Clinical trial results announced at the 61st annual meeting of the American Academy of Neurology suggest that the immunosuppressant drug cladribine (Leustatin, Ortho Biotech; marketed for the ...

Cladribine (2-chlorodeoxyadenosine) is a purine nucleoside analogue with activity against various hematologic cancers. 1 Because mast cells are derived from hematopoietic stem cells, 2 we evaluated ...

TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline BRCA Carriers With HER2-Negative Breast Cancer (the INFORM trial) Single-agent purine ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Patients with ...

April 30, 2009 (Seattle, Washington) — Full results of the Cladribine Tablets Treating MS Orally (CLARITY) trial of oral cladribine (Leustatin, Ortho Biotech) in patients with relapsing-remitting ...

Learn everything you need to know about Cladribine-pronunciation, uses, dosage guidelines, indications, and when to take or avoid it. Get up-to-date information on side effects, precautions, warnings, ...

External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer Patients with AdvSM (n = ...

A 54-year-old man received a diagnosis of nasal sarcoidosis in 1993, which was successfully treated with prednisone. In 1998, progressive blindness developed, and brain magnetic resonance imaging (MRI ...

Next review: This guidance will be reviewed if there is new evidence that is likely to change the recommendations. NICE has separately evaluated cladribine for highly active multiple sclerosis in NICE ...

Cladribine tablets are approved for several indications, namely highly active forms of relapsing-remitting MS and certain forms of leukemia. MS represents the largest market segment for the sale of ...